shuibingchen/PDAC_KRAS: A Pancreatic Cancer Organoid Platform Identifies an Inhibitor Specific to Mutant KRAS

KRAS mutations, mainly G12D and G12V, are found in more than 90% of pancreatic ductal adenocarcinoma (PDAC) cases. The success of drugs targeting KRASG12C suggests the potential for drugs specifically targeting these alternative PDAC-associated KRAS mutations. Here, we report a high throughput drug screening platform using a series of isogenic murine pancreatic organoids that are wildtype (WT) or contain common PDAC driver mutations, representing both classical and basal PDAC phenotypes. We screened over 6000 compounds and identified Perhexiline maleate, which can inhibit the growth and induce cell death of pancreatic organoids carrying the KrasG12D mutation both in vitro and in vivo as well as primary human PDAC organoids. Single-cell RNA-seq analysis suggests that the cholesterol synthesis pathway is upregulated specifically in the KRAS mutant organoids, including the key cholesterol synthesis regulator. Perhexiline maleate decreases SREBP2 expression levels and reverses the KRAS mutant-induced upregulation of the cholesterol synthesis pathway.